drugset / Trial / NCT07110441

Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers

NCT07110441

Phase 1 Completed 52 enrolled Genfit
Non-randomizedSequentialOpen-labelTreatment

Summary

A Phase 1, Open-Label Study to Assess Pharmacokinetics, Safety and Tolerability of G1090N in Healthy Subjects

Timeline

Start
2025-08-26
Primary completion
2025-12-01
Completion
2025-12-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitazoxanide Other / unclassified 300 mg
Subject Nitazoxanide Other / unclassified 600 mg
Subject Nitazoxanide Other / unclassified 900 mg
Subject Nitazoxanide Other / unclassified 1200 mg

Indications